Eevia Health

Retinari™ is a compound developed by Eevia Health to prevent Age-related Macular Degeneration (AMD). It has shown positive pre-clinical results but lacks funding for necessary safety studies to proceed with human testing. Despite high rankings in international funding competitions, Eevia did not secure funding and thus sold certain intellectual property rights to Havu Health Oy for KEUR 800. This sale, subject to fair value assessment and creditor consent, aims to commercialize the product. Eevia will receive shares in Havu Health Oy as payment. Eevia Health, founded in 2017, focuses on bioactive compounds from renewable resources and operates a green-chemistry facility in Finland.

Eevia Health's Board of Directors has decided to release the Q4-2024 interim report earlier than planned, now set for February 4 instead of February 14. This change allows insiders to participate in the ongoing rights issue without being restricted by a trading ban. Consequently, the subscription period for the rights issue has been extended by one week to give investors more time to consider their options after the report's release. The updated subscription timetable includes specific dates for trading and registration in Sweden and Finland. Smartius and Aqurat Fondkommission are providing legal and issuing services, respectively. Eevia Health, established in 2017, is a company focused on producing organic plant extracts for global health products, with a production facility in Finland. The press release clarifies that it is not an offer to trade securities and highlights that the rights issue will only be conducted in Sweden and Finland, with specific legal restrictions in other countries. The release also notes that forward-looking statements are not guarantees of future results and may change.

Eevia Health is hosting a digital webinar for shareholders, investors, and stakeholders to discuss its strategic reorientation, turnaround plan, and rights issue, along with a broader funding strategy. The webinars will be led by CEO Stein Ulve and Chairman Terry Virts, with support from CTO Petri Lackman and Commercial Director Erik Eide. Two sessions are scheduled: February 4 and February 6, 2025, both at 14:00 CET. Registration links are provided, and any issues can be addressed via email. Eevia Health, established in 2017, produces bioactive compounds from sustainably sourced plant materials, focusing on gut and related health areas. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. More information is available on their website and LinkedIn.

Eevia received sales orders totaling KEUR 66 from ten customers, including a new one, with orders primarily for bilberry products and Fenoprolic 70 Organic. Notable orders included KEUR 11 from a French partner and KEUR 8 from a European customer using bilberry extract in animal feed. A Finnish customer ordered KEUR 10 of bilberry products, and Select Ingredients placed an order for a US-based organic brand. A German customer ordered KEUR 10 of Fenoprolic 70 Organic through distributor Breko, and there were US orders for Feno-Chaga Organic and a small order for Feno-Ceraus 5 Organic. A new Latvian customer ordered KEUR 3 of bilberry extract. Most products are in stock, allowing immediate delivery, except for Feno-Ceraus 5, which Eevia can produce quickly. These are repeat orders, and further orders are expected. Eevia Health Plc, founded in 2017, produces organically certified plant extracts for global dietary supplements and food brands, focusing on health areas like gut and kidney health. The company operates a sustainable production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Eevia Health has released an investment teaser to inform shareholders and potential investors about its strategic reorientation and turnaround plan. The teaser includes information on the company's business, products, strategy, and details of a Rights Issue, available on their website. Investors should review the exemption document published on January 27, 2025. The Rights Issue timetable in 2025 includes trading and subscription periods in Sweden and Finland, with key dates from January 28 to February 17. Eevia Health, founded in 2017, produces bioactive compounds from sustainably sourced plant materials, focusing on health areas like gut and kidney health. The company operates an environmentally friendly production facility in Finland and is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. For more details, visit their website or contact CEO Stein Ulve.

Eevia Health Plc is conducting a Rights Issue to raise approximately SEK 12.1 million, before transaction costs, with a subscription price of SEK 0.09 per share. The issue is partially underwritten by external investors. The subscription period runs from late January to mid-February 2025 in Sweden and Finland. Unused subscription rights will become invalid after the trading period. Eevia aims to restructure its business by focusing on higher-margin health products and divesting certain assets to new start-ups, Havu Health Oy and Baccus Salas Oy, in exchange for shares. These divestments are contingent on non-dilutive funding. The company plans to use the proceeds from the Rights Issue for debt repayment, working capital, and R&D investments. Eevia also seeks to negotiate better terms for its unsecured debt. The strategic shift includes focusing on gut, kidney, and urinary health solutions and expanding its market share in the global ingredient market. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden.